Hepatitis C and HTV infection: Biological, clinical, and therapeutic implications

Journal of Hepatology, Supplement

Volumn 31, Issue 1, 1999, Pages 119-123

  Soriano, Vincent ^a,b   Garcia Samaniego, Javier ^a,b   Rodriguez Rosado, Rafaël ^a,b   Gonzalez, Juan ^a,b   Pedreira, José ^a,b  

^a INSTITUTO DE SALUD CARLOS III   (Spain)

^b NONE   (Spain)

Author keywords

Hepatitis c; HIV; Interferon; Liver disease; Ribavirin

Indexed keywords

ALPHA INTERFERON; ANTIVIRUS AGENT; RIBAVIRIN;

ADULT; CASE REPORT; CONFERENCE PAPER; DISEASE COURSE; HEMOLYTIC ANEMIA; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER TOXICITY; LYMPHOCYTOPENIA; MALE; MORTALITY; PRIORITY JOURNAL; RISK FACTOR; SUPERINFECTION;

ANTIVIRAL AGENTS; HEPATITIS C; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS;

EID: 0033405572     PISSN: 01695185     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Stubbe L, Soriano V, Antunes F et al. Hepatitis C in the EuroSIDA Cohort of European HIV-infected patients: prevalence and prognostic value [Abstract no. 22261]. 12th World AIDS Conference, Geneva, July; 1998.
2. Ockenga J, Tillmann H, Trautwein C et al. Hepatitis B and C in HIV-infected patients. Prevalence and prognostic value. J Hepatol 1997: 27: 18-24.
3. Eyster M, Diamondstone L, Lien J et al. Natural history of hepatitis C virus infection in multitransfused hemophiliacs: effect of coinfection with HIV. J AIDS Hum Retrovirol 1993: 6: 602-610.
4. Eyster M, Fried M, Di Bisceglie A et al. Increasing hepatitis C virus RNA levels in hemophiliacs: relationship to HIV infection and liver disease. Blood 1994: 84: 1020-1023.
5. Solo B, Sanchez-Quijano A, Rodrigo L, Leal M, Lissen E. HIV infection modifies the natural history of chronic parenterally acquired hepatitis C with an unusually rapid progression to cirrhosis. A multicenter study on 547 patients. J Hepatol 1997: 26: 1-5.
6. Telfer P, Sabin C, Deveraux H. The progression of HCV-associated liver disease in a cohort of haemophilia patients. Br J Haematol 1994: 87: 555-561.
7. Soriano V, Bravo R, Mas A et al. Impact of immunosuppression caused by HIV infection on the replication of hepatitis C virus. Vox Sang 1995: 69: 259-260.
8. Soriano V, Garcia-Samaniego J, Rodriguez-Rosado R, Valencia E, Munoz F, Gonzàlez-Lahoz J. Impact of chronic viral liver disease due to hepatitis viruses as cause of hospital admission and death in HIV-infected drug users. Eur J Epidemiol 1999: 27: 17.
9. Lesens O, Besehenes M, Stehen M, Belanger G, Tsoukas C. Hepatitis C virus is related to progressive liver disease in HIVpositive hemophiliacs and should be treated as an opportunistic infection. J Infect Dis 1999: 179: 1254-1258.
10. Piroth L, Duong M, Quantin C, Abrahamowicz M, Michardiere R, Aho L et al. Does hepatitis C virus co-infection accelerate clinical and immunological evolution of HIV-infected patients? AIDS 1998: 12: 381-388.
11. Rodriguez-Rosado R, Garcia-Samaniego J, Soriano V Hepatotoxicity after introduction of highly active antiretroviral therapy. AIDS 1998: 12: 1256.
12. John M, Flexman J, French M. Hepatitis C virus-associated hepatitis following treatment of HIV-infected patients with HIV protease inhibitors: an immune restoration disease? AIDS 1998: 12: 2289-2293.
13. Soriano V, Rodriguez-Rosado R, Garcia-Samaniego J. Management of chronic hepatitis C in HIV-infected patients. AIDS 1999: 13: 539-546.
14. Dieterich D, Purow J, Rajapaksa R. Activity of combination therapy with IFN2b plus ribavirin in chronic hepatitis C patients co-infected with HIV. Semin Liver Dis 1999: 19 (suppl. 1): 8794.
15. National Institutes of Health: Consensus Development Conference Panel Statement. Management of Hepatitis C. Hepatology 1997: 26 (Suppl 1): 2-10.
16. Soriano V, Garcia-Samaniego J, Bravo R, Gonzalez J, Castro A, Castilla J et al. Interferon alpha for the treatment of chronic hepatitis C in patients infected with human immunodeficiency virus. Clin Infect Dis 1996: 23: 585-591.
17. Soriano V, Bravo R, Garcia-Samaniego J, Castilla J, Gonzalez J, Castro A et al. Relapses of chronic hepatitis C in HIV-infected patients who responded to interferon therapy. AIDS 1997: 11: 400-401.
18. Garcia-Samaniego J, Soriano V, Castilla J, Bravo R, Moreno A, Carbo J et al. Influence of hepatitis C virus genotypes and HIV infection on histological severity of chronic hepatitis C. Am J Gastroenterol 1997: 92: 1130-1134.
19. Zeuzem S, Schmidt J, Lee J et al. Hepatitis C virus dynamics in vivo: effect of ribavirin and interferon alpha on viral turnover. Hepatology 1998: 28: 245-251.
20. Neumann A, Lam N, Dahari H et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 1998: 282: 103-107.
21. Enomoto E, Sakuma I, Asahina Y et al. Mutations in the nonstructural protein 5 gene and response to interferon in patients with chronic hepatitis C virus Ib infection. N Engl J Med 1996: 334: 77-81.
22. Quinones-Mateu M, Arts E. Recombination in HIV-1: update and implications. AIDS Reviews 1999: 1: 89-100.
23. Reichard O, Norkrans G, Fryden A et al. Randomised, doubleblind, placebo-controlled trial of interferon or-2b with and without ribavirin for chronic hepatitis C. Lancet 1998: 351: 83-87.
24. McHutchison J, Poynard T. Combination therapy with interferon plus ribavirin for the initial treatment of chronic hepatitis C. Semin Liver Dis 1999: 19 (suppl. 1): 57-65.
25. Gonzalez J, Garcia-Samaniego J, Arribas JR, Pena JM, Soriano V Interferon plus ribavirin for chronic hepatitis C in HIV-infected patients. AIDS 1999 (in press).
26. Brillant! S, Foli M, Di Tomaso M, Gramantieri L, Masci C, Bolondi L. Pilot study of triple antiviral therapy for chronic hepatitis C in interferon non-responders. Ital J Gastroenterol Hepatol 1999: 31: 130-134.
27. Younossi Z, Perrillo R. The roles of amantadine, rimantadine, UDCA, and NSAIDs, alone or in combination with interferon in the treatment of chronic hepatitis C. Semin Liver Dis 1999: 19: 95-102.
28. Martinot-Peignoux M, Marcellin P, Pouteau M et al. Pretreatment serum HCV RNA levels and hepatitis C virus genotype are the main and independent prognostic factors of sustained response to interferon alpha therapy in chronic hepatitis C. Hepatology 1995: 22: 1050-1056.
29. Ho D. Time to hit HIV, early and hard. N Engl J Med 1995: 333: 450-451.
30. Soriano V, Bravo R, Garcia-Samaniego J et al. CD4+ lymphocytopenia in HIV-infected patients ongoing interferon therapy for chronic hepatitis C. AIDS 1994: 8: 1621-1622.
31. Garcia-Samaniego J, Bravo R, Castilla J et al. Lack of benefit of protease inhibitors on HCV viremia in HIV-infected patients patients. J Hepatol 1998: 28: 526-527.
32. Bravo R, Soriano V, Garcia-Samaniego J et al. Impact of antiretroviral therapy on hepatitis C viremia in HIV-infected patients. Antiviral Therapy 1996: 1: 194.
33. Rutschmann O, Negro F, Hirschel B et al. Impact of treatment with HIV protease inhibitors on hepatitis C viremia in patients coinfected with HIV J Infect Dis 1998: 177: 783-785.
34. Pérez-OImeda M, Garcia-Samaniego J, Soriano V. Reduction in hepatitis C viremia occurs after prolonged periods of successful antiretroviral therapy in HCV-HIV coinfected patients. AIDS 1999 (in press).